Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy

Modern Pathology

Volumn 20, Issue 11, 2007, Pages 1172-1182

  Volante, Marco ^a   Brizzi, Maria Pia ^a   Faggiano, Antongiulio ^b   Rosa, Stefano La ^c   Rapa, Ida ^a   Ferrero, Anna ^a   Mansueto, Gelsomina ^b   Righi, Luisella ^a   Garancini, Silvana ^d   Capella, Carlo ^c   De Rosa, Gaetano ^b   Dogliotti, Luigi ^a   Colao, Annamaria ^b   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Immunohistochemistry; Neuroendocrine tumors; Scoring system; Somatostatin receptor; Somatostatin receptor scintigraphy

Indexed keywords

OCTREOTIDE; PENTETREOTIDE IN 111; RECEPTOR ANTIBODY; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ANTIBODY LABELING; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTASIS; METHODOLOGY; NEUROENDOCRINE TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; STAINING; TREATMENT RESPONSE; TUMOR SCINTISCANNING;

HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; PILOT PROJECTS; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 35348933794     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800954     Document Type: Article

References (26)

1. DeLellis RA, LLoyd R, Heitz PU (eds). World Health Organization Classification of Tumors, Pathology and Genetics - Tumors of Endocrine Organs. IARC Press: Lyon, 2004.
2. Solcia E, Kloppel G, Sobin LH. World Health Organization International histological classification of tumors. Histological typing of endocrine tumors. Springer: Berlin, 2000.
3. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 2004;43:626-636.
4. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004;43:617-625.
5. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-616.
6. Bloom SR, Mortimer CH, Thorner MO, et al. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974;2:1106-1109.
7. Epelbaum J. Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 1986;27:63-100.
8. Haroutunian V, Mantin R, Campbell GA, et al. Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res 1987;403:234-242.
9. Raynor K, Lucki I, Reisine T. Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats. J Pharmacol Exp Ther 1993;265:67-73.
10. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
11. Patel YC, Greenwood MT, Panetta R, et al. The somatostatin receptor family. Life Sci 1995;57:1249-1265.
12. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-442.
13. Hofland LJ, Liu Q, Van Koetsveld PM, et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999;84:775-780.
14. Janson ET, Gobl A, Kalkner KM, et al. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996;56:2561-2565.
15. Korner M, Eltschinger V, Waser B, et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005;29:1642-1651.
16. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60.
17. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003;88:5150-5157.
18. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001;439:787-797.
19. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461-475.
20. Reubi JC, Schaer JC, Waser B, et al. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54: 3455-3459.
21. Reubi JC, Kappeler A, Waser B, et al. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 1998;153:233-245.
22. Vikic-Topic S, Raisch KP, Kvols LK, et al. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 1995;80:2974-2979.
23. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with neuroendocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-2762.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
25. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol 2004;15:275-291.
26. Reubi JC, Waser B, Liu Q, et al. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous vs intracellular location. J Clin Endocrinol Metab 2000;85:3882-3891.